Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Accumulated Expenses (2023 - 2024)

Tonix Pharmaceuticals Holding has reported Accumulated Expenses over the past 2 years, most recently at $33000.0 for Q2 2024.

  • Quarterly results put Accumulated Expenses at $33000.0 for Q2 2024, changed N/A from a year ago — trailing twelve months through Jun 2024 was $33000.0 (changed N/A YoY), and the annual figure for FY2023 was $44000.0, changed.
  • Accumulated Expenses for Q2 2024 was $33000.0 at Tonix Pharmaceuticals Holding, down from $44000.0 in the prior quarter.
  • Over the last five years, Accumulated Expenses for TNXP hit a ceiling of $44000.0 in Q4 2023 and a floor of $32000.0 in Q3 2023.